Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald de Wit

Showing results (31-40 of 204) with videos related to

Pageof 21
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
Adding metabolic agents to prostate cancer therapy: Every rose has its thornStefan A J Buck, Ron H J Mathijssen, Ronald de Wit
European Urology|March 24, 2018
Cell-free DNA in Advanced Prostate Cancer: A Biomarker Revolution Under Way?Robert J van Soest, Bertrand Tombal, Martijn P Lolkema, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancerAndrew J Armstrong, Elizabeth Garrett-Mayer, Ronald de Wit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2012
Design of testis cancer trials: who knows best?Ronald de Wit, Gedske Daugaard, Peter Albers, et al.
Cancer Treatment Reviews|April 24, 2016
The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancerWendy Onstenk, Willemijn de Klaver, Ronald de Wit, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 15, 2013
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 studySaroj Niraula, Greg Pond, Ronald de Wit, et al.
Expert Opinion on Investigational Drugs|January 17, 2012
Danusertib, an aurora kinase inhibitorHielke J Meulenbeld, Ron Hj Mathijssen, Jaap Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2009
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survivalAndrew J Armstrong, Ian F Tannock, Ronald de Wit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyDominik R Berthold, Gregory R Pond, Freidele Soban, et al.
European Urology|February 7, 2019
Reply to Thomas Gevaert, Markus Eckstein, Rodolfo Montironi, and Antonio Lopez-Beltran's Letter to the Editor re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40Maud Rijnders, Astrid A M van der Veldt, Ronald de Wit, et al.
Pageof 21

Showing results (31-40 of 204) with videos related to

Sort By:
Pageof 21
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
Adding metabolic agents to prostate cancer therapy: Every rose has its thornStefan A J Buck, Ron H J Mathijssen, Ronald de Wit
European Urology|March 24, 2018
Cell-free DNA in Advanced Prostate Cancer: A Biomarker Revolution Under Way?Robert J van Soest, Bertrand Tombal, Martijn P Lolkema, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancerAndrew J Armstrong, Elizabeth Garrett-Mayer, Ronald de Wit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2012
Design of testis cancer trials: who knows best?Ronald de Wit, Gedske Daugaard, Peter Albers, et al.
Cancer Treatment Reviews|April 24, 2016
The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancerWendy Onstenk, Willemijn de Klaver, Ronald de Wit, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 15, 2013
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 studySaroj Niraula, Greg Pond, Ronald de Wit, et al.
Expert Opinion on Investigational Drugs|January 17, 2012
Danusertib, an aurora kinase inhibitorHielke J Meulenbeld, Ron Hj Mathijssen, Jaap Verweij, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2009
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survivalAndrew J Armstrong, Ian F Tannock, Ronald de Wit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2008
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyDominik R Berthold, Gregory R Pond, Freidele Soban, et al.
European Urology|February 7, 2019
Reply to Thomas Gevaert, Markus Eckstein, Rodolfo Montironi, and Antonio Lopez-Beltran's Letter to the Editor re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40Maud Rijnders, Astrid A M van der Veldt, Ronald de Wit, et al.
Pageof 21